NASDAQ: CTOR · Life Sciences · 4 alerts · CIK 1851484
Share price
$0.5350Close, Nov 16
Market cap
$49.7M
Shares outstanding
92.98MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Citius Oncology, Inc. filings on SEC EDGAR ↗
Citius Oncology announced positive health-related quality of life (HRQoL) results from its pivotal Study 302 of LYMPHIR in patients with relapsed or refractory cutaneous T-cell lymphoma. Data presented at the EORTC-CLTG 2026 Annual Meeting showed that patients who responded to treatment reported sustained improvements in skin-related quality of life and significant reductions in pruritus (itching).
Citius Oncology received a formal extension from Nasdaq until April 19, 2027, to regain compliance with the $1.00 minimum bid price requirement. To satisfy the rule, the company's common stock must close at or above $1.00 for at least ten consecutive business days. The stock continues to trade on the Nasdaq Capital Market under the symbol 'CTOR' while the company evaluates options to address the deficiency.